Otonomy Announces Commercial Availability of OTIPRIO™

Back to Jobs

SAN DIEGO , March 02, 2016 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the commercial launch of OTIPRIO (ciprofloxacin otic suspension)

Apply Now